A clinical-stage biotechnology company headquartered in Israel that specializes in macrophage reprogramming immunotherapy. The company develops Allocetra, a cell therapy platform designed to restore macrophage homeostasis for treating conditions including knee osteoarthritis, temporomandibular joint osteoarthritis, and organ failure in sepsis patients.